Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

PHASE2CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

June 30, 2013

Conditions
HIV-1 Infection
Interventions
DRUG

Cenicriviroc 100 mg

100 mg CVC plus Truvada

DRUG

Cenicriviroc 200 mg + Truvada

200 mg CVC plus Truvada

DRUG

Sustiva + Truvada

Sustiva plus Truvada

Trial Locations (48)

909

Clinical Research P.R., Inc., Santurce

935

Univ. of Puerto Rico - ACTU, San Juan

University of Puerto Rico, School of Medicine, CEMI, San Juan

10011

Bisher Akil, M.D., A Medical Corporation, New York

10016

Aaron Diamond AIDS Research Center, New York

10018

ACRIA, New York

10461

Jacobi Medical Center, New York

11230

Synergy First Medical PLLC, Brooklyn

14215

Erie County Medical Center Corporation, Buffalo

14607

AIDS Care, Rochester

19104

University of Pennsylvania Health System, Philadelphia

20007

Georgetown University Hospital, Washington D.C.

20009

Whitman-Walker Clinic, Washington D.C.

27599

University of North Carolina at Chapel Hill, Chapel Hill

28078

Rosedale Infectious Disease, Huntersville

30308

AIDS Research Consortium of Atlanta, Inc., Atlanta

31410

Chatham County Health Department, Savannah

32803

Orlando Immunology Center, Orlando

32960

Treasure Coast Infectious Disease Consultants, Vero Beach

33136

University of Miami School of Medicine, Miami

33137

Care Resource Inc., Miami

Kinder Medical Group, Miami

33139

Wohlfeiler, Piperato & Associates, LLC, Miami Beach

33308

Therafirst Medical Center, Fort Lauderdale

33316

Gary Richmond, Fort Lauderdale

33401

Triple O Research Institute, PA, West Palm Beach

34695

Health Positive, Safety Harbor

34982

Midway Immunology and Research Center, Ft. Pierce

35294

University of Alabama at Birmingham, Birmingham

48202

Henry Ford Health System, Detroit

75246

North Texas Infectious Diesease Consultants, Dallas

77004

Therapeutic Concepts, Houston

77030

The University of Texas Health Science Center at Houston Medical School, Houston

85006

Southwest Center for HIV / AIDS, Phoenix

90015

AIDS Research Alliance, Los Angeles

90036

Peter J Ruane MD Incorporated, Los Angeles

90059

Oasis Clinic, Los Angeles

90069

Anthony Mills, Los Angeles

90211

AIDS Healthcare Foundation Research Center, Beverly Hills

Pacific Oaks Medical Group, Beverly Hills

91505

Providence Clinical Research, Burbank

92663

Orange Coast Medical Group, Newport Beach

94110

University of California at San Francisco, San Francisco

94115

Quest Clinical Research, San Francisco

94304

Stanford University ACTU, Palo Alto

02215

Community Research Initiative of New England, Boston

08844

ID Care, Hillsborough

45267-0405

University of Cincinnati, Cincinnati

All Listed Sponsors
lead

Tobira Therapeutics, Inc.

INDUSTRY

NCT01338883 - Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus | Biotech Hunter | Biotech Hunter